Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Diabetes, Type 1 Clinical Trial

Official title:
A Phase3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With Lantus® Versus Humalog® in Combination With Lantus® in Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period

Status Terminated

Clinical Trial Summary

The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Diabetes, Type 1

Clinical Trial Details

NCT number	NCT00700622
Study type	Interventional
Source	Mannkind Corporation
Contact
Status	Terminated
Phase	Phase 3
Start date	May 2008
Completion date	March 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02601729` - Reimbursement Study of Continuous Glucose Monitoring in Belgium
Completed	`NCT01805414` - Breakfast Nutrition and Inpatient Glycemia	N/A
Completed	`NCT00308737` - Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes	Phase 3
Completed	`NCT02657213` - Study of Insulin Pump in Prevention of Low Glucose Events in Adults With Type 1 Diabetes at Risk of Severe Hypoglycemia	N/A
Terminated	`NCT01350102` - The Relationship of Hemoglobin A1c and Diabetic Wound Healing	Phase 4
Withdrawn	`NCT03494010` - Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant
Completed	`NCT02214719` - Edmonton Automated Sugar Intelligence - Intelligent Diabetes Management, EASI-IDM, App Program to Assist Diabetes Care	N/A